Advertisement
Canada markets close in 51 minutes
  • S&P/TSX

    21,884.03
    +155.48 (+0.72%)
     
  • S&P 500

    5,071.77
    +53.38 (+1.06%)
     
  • DOW

    38,278.01
    +374.72 (+0.99%)
     
  • CAD/USD

    0.7314
    +0.0032 (+0.45%)
     
  • CRUDE OIL

    79.11
    +0.11 (+0.14%)
     
  • Bitcoin CAD

    81,034.07
    +785.75 (+0.98%)
     
  • CMC Crypto 200

    1,278.31
    +7.56 (+0.59%)
     
  • GOLD FUTURES

    2,317.50
    +6.50 (+0.28%)
     
  • RUSSELL 2000

    2,014.50
    +34.27 (+1.73%)
     
  • 10-Yr Bond

    4.5710
    -0.0240 (-0.52%)
     
  • NASDAQ

    15,859.13
    +253.65 (+1.63%)
     
  • VOLATILITY

    14.75
    -0.64 (-4.16%)
     
  • FTSE

    8,172.15
    +50.91 (+0.63%)
     
  • NIKKEI 225

    38,236.07
    -37.98 (-0.10%)
     
  • CAD/EUR

    0.6815
    +0.0022 (+0.32%)
     

Syndax Announces Participation at the Stifel 2024 Virtual Targeted Oncology Forum

WALTHAM, Mass., April 10, 2024 /PRNewswire/ -- Syndax Pharmaceuticals (Nasdaq: SNDX), a clinical-stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today announced that Michael A. Metzger, Chief Executive Officer of Syndax, will participate in a fireside chat at the at Stifel 2024 Virtual Targeted Oncology Forum on Wednesday, April 17, 2024, at 11:00 a.m. ET.

A live webcast of the fireside chat can be accessed from the Investor section of the Company's website at www.syndax.com, where a replay of the event will also be available for a limited time.

About Syndax

Syndax Pharmaceuticals is a clinical stage biopharmaceutical company developing an innovative pipeline of cancer therapies. Highlights of the Company's pipeline include revumenib, a highly selective inhibitor of the menin–KMT2A binding interaction, and axatilimab, a monoclonal antibody that blocks the colony stimulating factor 1 (CSF-1) receptor. For more information, please visit. For more information, please visit www.syndax.com or follow the Company on X (formerly Twitter) and LinkedIn.

ADVERTISEMENT

Syndax Contact

Sharon Klahre
Syndax Pharmaceuticals, Inc.
sklahre@syndax.com
Tel 781.684.9827

SNDX-G

Cision
Cision

View original content:https://www.prnewswire.com/news-releases/syndax-announces-participation-at-the-stifel-2024-virtual-targeted-oncology-forum-302113234.html

SOURCE Syndax Pharmaceuticals, Inc.